2020 UAB Cardiovascular Institute Annual Report CVI Annual Report 2019-2020 6 | Page 12

IN-HOSPITAL TAVR MORTALITY
TAVR RISK-ADJUSTED MORTALITY
ODDS RATIO (R3Y): UAB COMPARED
TO TVT REGISTRY
UAB’s TAVR program continues to excel
with excellent outcomes, as evidenced
by these charts from the TVT/NCDR
registry 2019 Q1 report.
TAVR PROCEDURES: 2012-2019
As UAB’s TAVR volumes continue to increase, the in-house mortality rates have declined.
TRANSCATHETER APPROACH TO TAVR 2014-2019
UAB’s valve team has utilized various techniques for implantation of the TAVR valve, tailored to the needs
of the patient.
Transaxillary/subclavian 3.0%
(2.9% 2019 alone)
Transcarotid/
suprasternal 2.0%
(4.7% 2019 alone)
Transaortic 8.0%
(5.5% 2019 alone)
MITRACLIP MORTALITY OUTCOMES
COMPARED TO THE STS/TVT
REGISTRY
UAB’s structural heart and valve team
performed 85 MitraClip procedures in
2019, with mortality rates lower than
the STS/TVT registry benchmarks for
30-day and in-hospital mortality.
RESEARCH HIGHLIGHTS
UAB’s structural heart and valve team participates in industry-leading clinical trials involving the mitral and
tricuspid valves, such as:
• Summit/MAC – Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Mitral Valve System
for the Treatment of Symptomatic Mitral Regurgitation
• TRILUMINATE – Clinical Trial to Evaluate Cardiovascular Outcomes in Patients Treated with the Tricuspid Valve
Repair System Pivotal
TEAM APPROACH AVOIDS NEED FOR
EMERGENT TRANSPLANT SURGERY
The structural heart team, in close collaboration
with UAB pediatric congenital heart surgeons
and cardiologists, utilized a successful,
alternative-access suprasternal approach,
implanting a 34mm Pro Plus TAVR valve in a
14-year-old, avoiding the need for an emergent
heart transplant.
SELECTED PUBLICATIONS
• Ahmed MI, Arisha MJ, Nanda NC, Lewis CTP, Eudailey KW. Usefulness of two- and three-dimensional
transesophageal echocardiography in combined mitral valve-in-valve implantation and paraprosthetic leak
closure. Echocardiography. 2018 Apr;35(4):501-505.
• Chatterjee A, Hillegass WB. “Expanding the frame” for valve-in-valve therapy in small bioprostheses:
Encouraging signs for the road ahead. Catheter Cardiovasc Interv. 2018 Sep 1;92(3):555-556.
• Chatterjee A, Hillegass WB. Surgical aortic valve replacement and transcatheter aortic valve implantation
for severe aortic stenosis: Equipoise remains a tenable assumption. Catheter Cardiovasc Interv. 2018 Aug
1;92(2):431-432.
Transfemoral 86.0%
(87.0% 2019 alone)
10
UAB Cardiovascular Institute Annual Report
uabmedicine.org
11